Peptide 157 (BPC-157): Mechanism, Dosing Data, and Clinical Evidence
Isolated from a protective fragment of human gastric juice and first described by Croatian researcher Predrag Sikiric in 1993, BPC-157 has produced more published animal research than almost any other longevity peptide — yet it has no licensed human indication anywhere in the world. That gap between mechanistic evidence and regulatory status is exactly what makes peptide 157 one of the most searched, and most misunderstood, compounds in longevity medicine today.
Key Takeaways
- Peptide 157 (BPC-157) is a synthetic pentadecapeptide studied for its role in angiogenesis (new blood vessel formation) and neuroprotection, primarily in preclinical and early-phase research.
- Published research most commonly references single-dose protocols in the 50–100 μg range; dosing varies by route and by the condition under study.
- BPC-157 is not a licensed medicine in the UK and is prohibited in competitive sport by the World Anti-Doping Agency, so sourcing and medical oversight matter.
- KCM Clinic assesses BPC-157 as one component of its longevity and biological-age testing programme, alongside other biomarkers and peptide options.
- Evidence is genuinely early-stage. Individual response varies, and any peptide protocol should sit inside a supervised medical assessment, not a self-directed purchase.
What Is Peptide 157 (BPC-157) and What Does It Do?
Peptide 157, more precisely known as BPC-157, is a synthetic 15-amino-acid peptide derived from a protective compound found in human gastric juice. Researchers began studying it in the early 1990s for its apparent ability to accelerate healing in animal models of tendon, ligament, muscle, and gut tissue damage. Its full name — Body Protection Compound-157 — reflects that original research focus on gastrointestinal and musculoskeletal repair.
Two properties come up repeatedly in the literature: angiogenesis and neuroprotection. The table below summarises what the published research base actually covers, separate from marketing claims found on supplement retail sites.
| Research dimension | What the published data shows |
|---|---|
| First described | 1993, by Predrag Sikiric’s research group (Croatia) |
| Molecular structure | 15-amino-acid synthetic pentadecapeptide |
| Primary evidence base | Predominantly animal-model and preclinical studies; limited early-phase human research |
| Core mechanisms studied | Angiogenesis (VEGF-related pathways), neuroprotection, modulation of nitric oxide signalling |
| Typical research dosing | 50–100 μg per administration in published protocols |
| Regulatory status (UK/EU) | Not a licensed medicine; not approved for human use outside research contexts |
| Regulatory status (US) | Excluded by the FDA from its list of bulk substances eligible for compounding |
| Sport status | Prohibited substance under the WADA Prohibited List |
How Does the BPC-157 Mechanism Work at the Cellular Level?
BPC-157’s two most-cited mechanisms are angiogenesis and neuroprotection, both linked in preclinical research to how the peptide interacts with growth-factor and nitric oxide signalling pathways. In animal models, BPC-157 has been shown to upregulate pathways associated with VEGF receptor activity, which supports the formation of new blood vessels around injured tissue. Faster local blood supply is one proposed reason tendon and gut-lining models in these studies showed accelerated repair.
The neuroprotective research strand is separate but related. Several published studies describe BPC-157 modulating nitric oxide activity and reducing markers of oxidative stress in nerve tissue models, which is why longevity researchers have taken an interest beyond the original musculoskeletal focus.
Tissue-repair mechanisms of this kind also come up in surgical recovery contexts — patients researching laminectomy recovery timelines will recognise the same angiogenesis-driven healing logic, even though that procedure has nothing to do with peptide therapy directly.
Angiogenesis and neuroprotection are the two mechanisms most consistently described across published BPC-157 research.
By the numbers: A search of the peer-reviewed literature on BPC-157 returns a research base still overwhelmingly built on animal models — human trial data remains a small fraction of the total published work, which is why dosing recommendations stay conservative.
What Are the Clinical Research Findings on BPC-157 Dosing?
Published research on BPC-157 most often references single-dose protocols in the 50–100 μg range, with the exact figure depending on the condition being studied and the route of administration. Subcutaneous and intravenous routes dominate the research literature; oral formulations exist but face limited bioavailability data, since the peptide’s stability after digestion is harder to establish than for injectable routes.
Dosing intervals and duration also vary considerably between the animal studies that make up most of the evidence base. This is a critical distinction for anyone comparing a supplement listing to actual research: the doses cited on retail peptide sites are frequently extrapolated from animal-model body-weight ratios, not validated human protocols.
Dosing decisions for research peptides belong in a supervised clinical consultation, not a self-administered protocol.
- Single-dose range most cited in published research: 50–100 μg
- Primary routes studied: subcutaneous and intravenous
- Oral bioavailability: limited and inconsistently documented
- Duration and frequency: highly protocol-dependent, not standardised
Is Peptide 157 (BPC-157) Legal to Access in the UK?
BPC-157 is not licensed as a medicine in the UK, which means no pharmacy can dispense it against a standard NHS or private prescription in the way a licensed drug would be. It also sits on the World Anti-Doping Agency’s Prohibited List, so competitive athletes need to treat it as an off-limits substance regardless of source. UK buyers who purchase it online as a “research chemical” are, in practice, sourcing an unregulated product with no guarantee of purity, concentration, or sterility.
This is the same grey area covered in our broader guide to UK peptides and their legal status, which explains why physician-supervised access differs meaningfully from an unsupervised online purchase. Verified sourcing and medical oversight are the two variables that separate a legitimate longevity-clinic assessment from a research-chemical gamble.
Reality check: A product labelled “not for human consumption” is a regulatory disclaimer, not a suggestion. Any BPC-157 protocol pursued outside licensed medical supervision carries sourcing and purity risks that published research doesn’t account for.
What Is the Difference Between BPC-157 and Other Longevity Peptides?
BPC-157 is studied mainly for tissue repair and neuroprotection, while other longevity peptides target distinct mechanisms — NAD+ precursors focus on cellular energy metabolism, and growth-hormone-releasing peptides target muscle and recovery pathways. Comparing them side by side helps explain why a longevity programme typically evaluates several peptides rather than treating any single one as a universal solution.
| Peptide | Primary research focus | Typical administration |
|---|---|---|
| BPC-157 | Angiogenesis, tissue repair, neuroprotection | Subcutaneous, IV |
| NAD+ precursors (e.g., NMN pathways) | Cellular energy metabolism, mitochondrial function | Oral, IV |
| GHRPs (e.g., ipamorelin-class peptides) | Growth hormone release, recovery, body composition | Subcutaneous |
| Thymosin-class peptides | Immune modulation, tissue repair | Subcutaneous |
How Does BPC-157 Fit Into KCM Clinic’s Longevity and Biological-Age Testing Programme?
KCM Clinic’s longevity programme evaluates peptide options such as BPC-157 alongside a wider panel of biomarkers.
KCM Clinic treats BPC-157 as one option within a broader longevity and biological-age testing programme, assessed alongside biomarker panels rather than prescribed as a standalone product. That means a patient’s bloodwork, inflammatory markers, and biological-age indicators inform whether a peptide protocol is appropriate at all, before any specific peptide is discussed. Bone-density biomarkers are part of that same panel, which is also why patients weighing osteoporosis treatment options often start with the same longevity workup. Our approach pairs this kind of biomarker optimisation with the same comprehensive health screening process used across KCM’s other longevity services.
This is also where the EU-standards difference matters most: assessment happens under physician oversight, with sourcing and documentation that a research-chemical purchase simply cannot match. Peptide therapies at KCM sit inside a consultation model, not a checkout page.
Book a Longevity Consultation with KCM Clinic
If you’re weighing peptide 157 against other longevity options, the right next step is a conversation with a clinician who can assess your bloodwork and goals directly, not a forum thread. KCM Clinic’s longevity programme starts with that assessment.
Book a Longevity Consultation with KCM Clinic
FAQ: Peptide 157 (BPC-157) Common Questions
Is BPC-157 hard on the liver or kidneys?
Published animal research has not shown consistent liver or kidney toxicity at studied research doses, but comprehensive human safety data is still limited. Anyone considering a peptide protocol should have baseline liver and kidney function checked first, which is standard practice within a supervised longevity assessment.
Does BPC-157 work immediately?
No. Published research describes effects building over a course of administration rather than a single dose producing an instant change, particularly for the tissue-repair mechanisms most studied. Timeframes in the animal literature vary by condition, which is why individual response cannot be predicted from a fixed schedule.
Is peptide 157 legal to buy in the UK?
BPC-157 is not licensed as a medicine in the UK and is prohibited in competitive sport under WADA rules. It can be accessed through private longevity clinics with medical oversight, but unsupervised online purchases as a “research chemical” carry real sourcing and purity risks.
How much does BPC-157 therapy cost at KCM Clinic?
Cost depends on the biomarker testing and consultation scope each patient needs, so KCM Clinic doesn’t quote a fixed peptide-157 price without an assessment first. Booking a longevity consultation is the way to get an accurate, personalised figure rather than an estimated number.
